This EOM Pharmaceuticals website may contain information, news, and/or press releases, the content of which is accurate or current only as of the date of the particular information, news, press release, or posting. EOM does not update press releases once they have been made public.
MONTVALE, N.J. – August 24, 2021 — EOM Pharmaceuticals, Inc., a privately held, clinical-stage company, announced the first patients have been dosed in R1: RESCUE, a proof-of-concept Phase 1/2a open-label multicenter clinical study in Brazil to evaluate safety, tolerability, and preliminary efficacy of EOM613 in hospitalized COVID-19 infected patients with severe symptoms.
MONTVALE, N.J. – July 20, 2021 — EOM Pharmaceuticals, Inc., a privately-held, clinical-stage company, today announced the appointment of Frank L. Douglas, Ph.D., M.D., to Scientific Advisor. Dr. Douglas will be responsible for guiding the company’s clinical and scientific strategies for EOM lead candidate EOM613, as well as forming and chairing the EOM Scientific Advisory […]